Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) EBT Margin: 2022-2025

Historic EBT Margin for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to 1,893.60%.

  • Centessa Pharmaceuticals' EBT Margin rose 25269.00% to 1,893.60% in Q3 2025 from the same period last year, while for Sep 2025 it was -3,546.87%, marking a year-over-year decrease of 510199.00%. This contributed to the annual value of 2,308.35% for FY2024, which is 487863.00% up from last year.
  • According to the latest figures from Q3 2025, Centessa Pharmaceuticals' EBT Margin is 1,893.60%, which was up 10.18% from 1,718.62% recorded in Q2 2025.
  • Centessa Pharmaceuticals' EBT Margin's 5-year high stood at 4,448.53% during Q4 2024, with a 5-year trough of -164.92% in Q1 2025.
  • In the last 3 years, Centessa Pharmaceuticals' EBT Margin had a median value of 1,707.37% in 2024 and averaged 1,807.43%.
  • As far as peak fluctuations go, Centessa Pharmaceuticals' EBT Margin tumbled by 191,564bps in 2023, and later surged by 305,969bps in 2024.
  • Centessa Pharmaceuticals' EBT Margin (Quarterly) stood at 1,989.88% in 2022, then slumped by 60,104bps to 1,388.83% in 2023, then spiked by 305,969bps to 4,448.53% in 2024, then skyrocketed by 25,269bps to 1,893.60% in 2025.
  • Its EBT Margin was 1,893.60% in Q3 2025, compared to 1,718.62% in Q2 2025 and -164.92% in Q1 2025.